GlassScriptPhysician profile
Elizabeth Cockerill
NPI 1124259064
$2,585.24
in general payments reported to CMS, 2019-2025
21 companies · $458 in 2025
The $458 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $156 · 2021: $82.58 · 2022: $321 · 2023: $403 · 2024: $980 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $436.11 | 2022-2024 | |
| Alcon Vision LLC | $346.60 | 2021-2025 | Tryptyr, Rocklatan, Argos |
| Abbvie INC. | $309.82 | 2022-2024 | Vuity, Lumigan, Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $279.19 | 2023-2025 | Biotrue One Day, Infuse, Miebo |
| Oyster Point Pharma, INC. | $212.97 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $116.99 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $110.73 | 2024 | Syfovre |
| Allergan, INC. | $107.89 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $102.88 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.63 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $89.23 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $59.20 | 2024 | Acuvue |
| Kala Pharmaceuticals, INC. | $57.06 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $54.07 | 2022-2023 | Flarex |
| Thea Pharma INC. | $36.95 | 2024 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $36.41 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $31.19 | 2019-2021 | |
| Coopervision INC. | $29.43 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $26.77 | 2019-2020 | |
| Lombart Brothers, INC. | $19.72 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Cockerill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.